The National Institutes of Health has persuaded 10 rival drugmakers to briefly set aside their competitive spirits and collaborate on drug discovery projects in four major diseases, pooling their data and expertise to kick-start early-stage efforts.
Children as young as 2 years old can now use the latest in diabetes technology, even as the company that developed it is in a race to make it yesterday's news. The FDA announced Monday it has approved a pediatric version of DexCom's G4 Platinum. The San Diego med tech now has the first continuous glucose monitor (CGM) approved in the U.S. for toddlers.
When the Centers for Disease Control and Prevention looked into the reasons behind low uptake of GlaxoSmithKline's and Merck's human papillomavirus vaccines last year, the effect of parental attitudes to sex grabbed the headlines. Yet while parents may fear the vaccine will lead to risky sex, all the evidence suggests otherwise.
A year ago, it was quite the thing in Silicon Valley to invest in a coffee shop. Now, interest appears to be shifting in favor of medical devices. Executives from Apple Inc. met with FDA regulators in December. The meeting, noted in the FDA's public calendar, came just a few days before members of an elite Google R&D team held a tete a tete with some of the same regulatory officials.
The healthcare burdens of aging populations have traditionally been a Western problem, but rising life expectancy in emerging markets has caused the pressures to spread around the world. In India, the co-founder of IT services firm Infosys has responded by funding a brain and computing research center to improve the health of the 100 million citizens aged over 60.
Empiriko is working with CreaGen Biosciences to make its technology that mimics metabolism by liver enzymes more widely available to drug developers.
R&D software developer Accelrys has spent the four years since it merged with Symyx gobbling up a string of smaller companies. Yet this week Accelrys' management found themselves at the opposite end of the deal negotiating table and have struck a $750 million deal to sell the company.
Novartis' 500 Swiss job cuts announced earlier this month are just the tip of a global iceberg. The company plans to cut or shuffle up to 4,000 jobs in its pharma business, with many of the positions moving to a new operations center in Hyderabad, India, a Swiss newspaper reports.
Merck has joined the growing list of entities pulling the plug on chimpanzee research, folding to activist pressure and dismissing its primate subjects once and for all.
The big question at the beginning of this year was whether investors would continue to eagerly buy up shares offered in new biotech IPOs, continuing the burst of new offerings that injected billions of dollars into the industry last year. As of today, the answer--for at least a few select biotechs--is a boisterous "yes."